Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (24)	1/17/2001 10:30:43 PM
From: prophet_often	Respond to of 897

Here is a better link: quote.bloomberg.com <<<"Immunex has said it's rushing to complete a plant in Rhode Island and boost production elsewhere. ``Enbrel demand remains strong; however, the $100 million of additional supply, the increases in production yield and the Rhode Island facility will not likely impact capacity until the second half of 2001,'' Ende said in a note to clients. The company has said manufacturing capacity will limit the growth of Enbrel sales and that it has enough capacity to produce about $750 million of the drug this year. Immunex has said it's discussing production of another $100 million of the drug with its outside manufacturer, Boehringer Ingelheim GmbH.">>> I really do not know if shelf life is an issue. To me, this is poor planning on IMNX part. Why have they not addressed production shortages earlier? The other possibility is that they are hiding the fact they are having problems in the manufacturing process. PO